doxazosin has been researched along with Disease Models, Animal in 23 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxazosin decreases voluntary alcohol consumption by male alcohol-preferring (P) rats, supporting a role for the noradrenergic system in alcohol drinking in P rats and suggesting that doxazosin could potentially be an effective once-daily pharmacotherapeutic agent for the treatment of alcohol use disorders." | 7.79 | The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats. ( Beckwith, LE; Kincaid, CL; O'Neil, ML; Rasmussen, DD, 2013) |
| "To examine the anti-inflammatory effects of doxazosin in rodent models of inflammation." | 7.79 | Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. ( Cheung, PH; Ciallella, J; Saha, S; Tung, D, 2013) |
| "Doxazosin treatment prevented impaired vasodilatory response to SNP." | 5.31 | [Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. ( Cabestrero, F; Casado, S; de Andrés, R; Farré, J; Fortes, J; Gómez, J; López-Farré, A; Núñez, A; Rico, L; Rodríguez-Feo, JA, 2001) |
| " The present study analyzed the effect of bone morphogenetic protein (BMP)‑7 gene therapy with or without co‑treatment with doxazosin in a model of liver cirrhosis in hamsters." | 3.85 | Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model. ( Aldaba-Muruato, LR; Borrego-Soto, G; Cervantes-Garcia, D; Cuellar-Juarez, AG; Muñoz-Ortega, MH; Rojas-Martinez, A; Salinas, E; Ventura-Juarez, J, 2017) |
| "Doxazosin decreases voluntary alcohol consumption by male alcohol-preferring (P) rats, supporting a role for the noradrenergic system in alcohol drinking in P rats and suggesting that doxazosin could potentially be an effective once-daily pharmacotherapeutic agent for the treatment of alcohol use disorders." | 3.79 | The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats. ( Beckwith, LE; Kincaid, CL; O'Neil, ML; Rasmussen, DD, 2013) |
| "To examine the anti-inflammatory effects of doxazosin in rodent models of inflammation." | 3.79 | Novel anti-inflammatory effects of doxazosin in rodent models of inflammation. ( Cheung, PH; Ciallella, J; Saha, S; Tung, D, 2013) |
| "To study the possible relationship between adrenergic activities and the pathogenesis of benign prostatic hyperplasia (BPH), we tested the effect of doxazosin, an alpha 1-adrenoceptor antagonist, on prostatic growth in vivo using a mouse model for BPH." | 3.69 | Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. ( Park, SH; Thompson, TC; Timme, TL; Wu, X; Wyllie, MG; Yang, G, 1997) |
| "The effect of doxazosin administration on hemodynamics, hemostasis, and serum lipid and lipoprotein levels was investigated in cynomolgus monkeys (Macaca fascicularis) with diet-induced hypercholesterolemia." | 3.67 | Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys. ( Karge, WH; Kowala, MC; Nicolosi, RJ; Weiner, EJ, 1989) |
| " Prazosin prevented hepatotoxicity when administered 1 h before a toxic paracetamol insult and importantly, when administered up to 1 h post paracetamol injection." | 1.35 | alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. ( Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP, 2008) |
| "The doxazosin treatment did not further decrease the expression of an already low level of Bcl-2 in all prostate tumors, but it increased the expression of Bax, and the activation of caspase-3, and the cleavage of a downstream substrate, PARP." | 1.33 | Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. ( Chiang, CF; Son, EL; Wu, GJ, 2005) |
| "Doxazosin treatment prevented impaired vasodilatory response to SNP." | 1.31 | [Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. ( Cabestrero, F; Casado, S; de Andrés, R; Farré, J; Fortes, J; Gómez, J; López-Farré, A; Núñez, A; Rico, L; Rodríguez-Feo, JA, 2001) |
| "In previously untreated rats, pretreatment with enalaprilat shifted the dose-response curve for the hypotensive effect of doxazosin to the left, indicating synergism." | 1.28 | A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats. ( Marwood, JF; Stokes, GS; Tierney, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kaur, K | 1 |
| Singh, N | 1 |
| Dhawan, RK | 1 |
| Xiu, AY | 1 |
| Ding, Q | 1 |
| Li, Z | 1 |
| Zhang, CQ | 1 |
| Cervantes-Garcia, D | 1 |
| Cuellar-Juarez, AG | 1 |
| Borrego-Soto, G | 1 |
| Rojas-Martinez, A | 1 |
| Aldaba-Muruato, LR | 1 |
| Salinas, E | 1 |
| Ventura-Juarez, J | 1 |
| Muñoz-Ortega, MH | 1 |
| Li, T | 1 |
| Yang, S | 1 |
| She, X | 1 |
| Yan, Q | 1 |
| Zhang, P | 1 |
| Zhu, H | 1 |
| Wang, F | 1 |
| Luo, X | 1 |
| Sun, X | 1 |
| Chen, Y | 1 |
| Palczewska, G | 1 |
| Mustafi, D | 1 |
| Golczak, M | 1 |
| Dong, Z | 1 |
| Sawada, O | 1 |
| Maeda, T | 1 |
| Maeda, A | 1 |
| Palczewski, K | 1 |
| Gumrah, A | 1 |
| Tanidir, Y | 1 |
| Tinay, I | 1 |
| Ozyurek, M | 1 |
| Tarcan, T | 1 |
| Fornari, A | 1 |
| Rhoden, EL | 1 |
| Zettler, CG | 1 |
| Ribeiro, EP | 1 |
| Rhoden, CR | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 1 |
| Mifune, H | 1 |
| O'Neil, ML | 1 |
| Beckwith, LE | 1 |
| Kincaid, CL | 1 |
| Rasmussen, DD | 1 |
| Tung, D | 1 |
| Ciallella, J | 1 |
| Cheung, PH | 1 |
| Saha, S | 1 |
| Leggio, L | 1 |
| Kenna, GA | 1 |
| Takao, T | 1 |
| Tsujimura, A | 1 |
| Coetzee, S | 1 |
| Salm, SN | 1 |
| Lepor, H | 1 |
| Shapiro, E | 1 |
| Moscatelli, D | 1 |
| Wilson, EL | 1 |
| Chiang, CF | 1 |
| Son, EL | 1 |
| Wu, GJ | 1 |
| Randle, LE | 1 |
| Sathish, JG | 1 |
| Kitteringham, NR | 1 |
| Macdonald, I | 1 |
| Williams, DP | 1 |
| Park, BK | 1 |
| Yang, G | 1 |
| Timme, TL | 1 |
| Park, SH | 1 |
| Wu, X | 1 |
| Wyllie, MG | 1 |
| Thompson, TC | 1 |
| Buttyan, R | 1 |
| Reddi, AS | 1 |
| Nimmagadda, VR | 1 |
| Arora, R | 1 |
| Rodríguez-Feo, JA | 1 |
| Gómez, J | 1 |
| Núñez, A | 1 |
| Rico, L | 1 |
| Fortes, J | 1 |
| de Andrés, R | 1 |
| Cabestrero, F | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Marwood, JF | 1 |
| Tierney, G | 1 |
| Stokes, GS | 1 |
| Karge, WH | 1 |
| Kowala, MC | 1 |
| Weiner, EJ | 1 |
| Nicolosi, RJ | 1 |
| Swindell, AC | 1 |
| Valentine, JJ | 1 |
23 other studies available for doxazosin and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Potential role of EphrinA2 receptors in postconditioning induced cardioprotection in rats.
Topics: Animals; Creatine Kinase; Disease Models, Animal; Doxazosin; Female; Hemodynamics; Isolated Heart Pr | 2020 |
Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Autophagy; Carbon Tetrachloride; Cell L | 2021 |
Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model.
Topics: Adenoviridae; Adrenergic alpha-Antagonists; Animals; Bone Morphogenetic Protein 7; Collagen Type I; | 2017 |
Modulation of α-adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Di | 2019 |
Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration.
Topics: Adenine; Adenylyl Cyclase Inhibitors; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Alcoh | 2013 |
The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Carbachol; Disease Models, Animal; Doxazosin; Male | 2017 |
Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Animals; Disease Models, Anim | 2011 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Animals; Choice Behavior; Disease Models, | 2013 |
Novel anti-inflammatory effects of doxazosin in rodent models of inflammation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Chemokine CCL2; Disease | 2013 |
Commentary: Doxazosin for alcoholism.
Topics: Adrenergic alpha-1 Receptor Antagonists; Alcohol Drinking; Alcoholism; Animals; Disease Models, Anim | 2013 |
Stromal/epithelial interactions of murine prostatic cell lines in vivo: a model for benign prostatic hyperplasia and the effect of doxazosin on tissue size.
Topics: Adrenergic alpha-Antagonists; Animals; Cell Communication; Cell Line; Disease Models, Animal; Doxazo | 2003 |
Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
Topics: Adrenergic alpha-Antagonists; Androgen-Binding Protein; Animals; Antigens, CD; bcl-2-Associated X Pr | 2005 |
alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice.
Topics: Acetaminophen; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Catec | 2008 |
Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxazosin | 1997 |
The mouse prostate reconstitution model of prostate diseases.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxazosin | 1997 |
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Ag | 2001 |
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Doxazosin; Guanylate Cycla | 2001 |
A study of the interaction between the hypotensive actions of doxazosin and enalaprilat in anaesthetized rats.
Topics: Anesthesia; Animals; Antihypertensive Agents; Desoxycorticosterone; Disease Models, Animal; Dose-Res | 1992 |
Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Apolipoproteins B; Disease Models, Animal; Doxazosin; Hemodyn | 1989 |
Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
Topics: Adrenergic alpha-Antagonists; Animals; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Dise | 1987 |